Navigation Links
Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results
Date:11/13/2008

MONTVALE, N.J., Nov. 13 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY), today reported its financial results for the third quarter ended September 30, 2008.

"Our results reflect continued clinical progress on our programs and our commitment to translate that progress into innovative therapies," stated Vaughn M. Kailian, President and Chief Executive Officer of Memory Pharmaceuticals. "We expanded our agreement with Roche to enhance our ongoing Phase 2 trial for R3487/MEM 3454 in cognitive impairment associated with schizophrenia, or CIAS, resulting in accelerated milestone payments to Memory. We have been pleased with the pace of enrollment in the Phase 2 CIAS trial, and we expect to achieve our enrollment goal for the trial shortly, which will trigger a $5.0 million payment from Roche. During the quarter, we also achieved a milestone related to the Phase 2 CIAS trial under our equity financing agreement with SMRI, triggering an additional investment by the firm. In addition, we completed the final study in our Phase 1 program for R4996/MEM 63908 and are on track to report top-line results from the entire program before year-end."

Financial Results

For the quarter ended September 30, 2008, the Company reported a net loss of $8.9 million, or $0.11 per share, compared to a net loss of $6.2 million, or $0.09 per share, for the same period in 2007. For the nine months ended September 30, 2008, the Company reported a net loss of $34.8 million, or $0.46 per share, compared to a net loss of $25.7 million, or $0.36 per share, for the same period in 2007.

For the quarter ended September 30, 2008, the Company reported revenue of $4.3 million, compared to revenue of $5.0 million for the same period
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Miniaturizing memory: Taking data storage to the molecular level
2. Memory Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
3. Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements
4. Memory Pharmaceuticals Provides Update on NASDAQ Listing Status
5. Memoirs of a qubit: Hybrid memory solves key problem for quantum computing
6. Blanchette Rockefeller Neurosciences Institute Hosts First-Ever International Forum on Memory and Memory Disorders and Dedicates New $30 Million Research Facility
7. Jellyfish Protein Shows Potential to Help With Memory
8. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
9. SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications
10. Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute
11. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, April ... Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... nonprofit organization solely dedicated to finding a cure for hepatitis ... worldwide, will host its annual Crystal Ball on Friday, April ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: ... and commercializing innovative therapies addressing major unmet medical ... received the Notice of Allowance from the United ... self-delivering RNAi compounds (sd-rxRNA®), for the treatment of ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... 23, 2012 SiREM ( www.siremlab.com ) and ... signing of a Sales Agency Agreement between the ... Tersus Environmental will market, promote and sell SiREM,s ... as well as Gene-Trac® molecular testing services and ...
... Mich. and AMSTERDAM, Feb. 23, 2012   Rubicon ... sample-specific pre-analytical processes to improve the capabilities ... platforms, today announced a clinical supply agreement ... TransPLEX® whole genome RNA amplification technology.  Agendia ...
... Inc. (OTCBB: AMBS), a biotechnology company developing MANF, ... Gerald E. Commissiong, President and CEO, will present ... National Investment Banking Association (NIBA) conference on Thursday, ... Pavillon Hotel in New Orleans, LA. Mr. Commissiong ...
Cached Biology Technology:Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics 2Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics 3Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans 2
(Date:4/17/2014)... study suggests that fish consumption advisories for expecting ... long-lived contaminants like persistent organic pollutants (POPs). ... researchers including University of Toronto Scarborough PhD student ... how different levels of environmental contamination, a mother,s ... in the body influenced exposure in her children. ...
(Date:4/17/2014)... hundred births, Down syndrome - or trisomy 21 - ... It results from a chromosomal abnormality where cells of ... (1% of the human genome). A study conducted by ... Genetic Medicine and Development at the University of Geneva ... shed light on how the extra chromosome 21 upsets ...
(Date:4/17/2014)... in bone marrow need to produce hydrogen sulfide in ... to a new study from the Center for Craniofacial ... of USC. , Professor Songtao Shi, principal investigator on ... by the cells governs the flow of calcium ions. ... that results in osteogenesis, or the creation of new ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3
... PHILADELPHIA People with the heritable disorder of the ... develop basal cell carcinoma of the skin may have ... According to results of a placebo-controlled, randomized, double-blind, Phase ... inhibiting the development of basal cell carcinomas in a ...
... being recognized for devising a new way to study a ... investigating its role in the communication of important genetic messages ... Last year, the team, led by J. Andrew Hockert, at ... Health Science Center School of Medicine, put in its crosshairs ...
... HILL Bacteria can swim, propelling themselves through fluids using ... strolling along solid surfaces using little fibrous legs called pili. ... establish the infections such as meningitis that cause ... Now researchers at the University of North Carolina at Chapel ...
Cached Biology News:Celebrex inhibited the burden of skin cancer in high-risk patients 2Researchers pin down long-elusive protein that's essential to 'life as we know it' 2Researchers pin down long-elusive protein that's essential to 'life as we know it' 3A single atom controls motility required for bacterial infection 2A single atom controls motility required for bacterial infection 3
... the cost-effective solution for entry level imaging ... research imaging tasks, MetaVue enables time lapse, ... analysis. Compatibility with MetaMorphs extensive and ... has the power to drive motorized microscopes, ...
... for microRNA expression profiling ,miRCURY ... Locked Nucleic Acid (LNA) technology to provide ... short microRNA (miRNA) targets. miRCURY LNA Arrays ... RNA (no need for microRNA enrichment) labeled ...
... XL extends the MSn performance of the ... tools to generate extensive structural information for ... , Multiple dissociation techniques (PQD, ETD, ... unpredicted metabolites , Fast polarity switching for ...
For removal of the zona pellucida. Sterile, Mouse Embryo tested...
Biology Products: